open access

Vol 7, No 1 (2011)
Review paper
Published online: 2011-04-28
Get Citation

Treatment of advanced non-small cell lung cancer in the elderly

Magdalena Knetki-Wróblewska, Adam Płużański, Maciej Krzakowski
Onkol. Prak. Klin 2011;7(1):1-8.

open access

Vol 7, No 1 (2011)
REVIEW ARTICLES
Published online: 2011-04-28

Abstract

Non-small cell lung cancer (NSCLC) represents 80% of primary lung neoplasm’s. About 50% of diagnosed NSCLC occur in patients aged over 65 years old. Age is not an exclusion criterium but careful assessment of the performance status of patients should be performed. Short daily functional assessment and comprehensive geriatric assessment in selected patients can be helpful in qualifying to systemic treatment. Results of randomized clinical trials confirm effectiveness of two-drug cisplatin-based chemotherapy in first line treatment of the patients in good performance status. A monotherapy with third-generation drug and — in selected patients — gefitinib treatment is optional. Second-line therapy in elderly is safe and effective. Majority of recommendations are based on retrospective analysis. Randomized prospective elderly-specific NSCLC trials are necessary to practically evaluate role of tests of geriatric assessments and effectiveness of chemotherapy.

Onkol. Prak. Klin. 2011; 7, 1: 1–8

Abstract

Non-small cell lung cancer (NSCLC) represents 80% of primary lung neoplasm’s. About 50% of diagnosed NSCLC occur in patients aged over 65 years old. Age is not an exclusion criterium but careful assessment of the performance status of patients should be performed. Short daily functional assessment and comprehensive geriatric assessment in selected patients can be helpful in qualifying to systemic treatment. Results of randomized clinical trials confirm effectiveness of two-drug cisplatin-based chemotherapy in first line treatment of the patients in good performance status. A monotherapy with third-generation drug and — in selected patients — gefitinib treatment is optional. Second-line therapy in elderly is safe and effective. Majority of recommendations are based on retrospective analysis. Randomized prospective elderly-specific NSCLC trials are necessary to practically evaluate role of tests of geriatric assessments and effectiveness of chemotherapy.

Onkol. Prak. Klin. 2011; 7, 1: 1–8

Get Citation

Keywords

non-small-cell lung cancer; chemotherapy; elderly; geriatric oncology

About this article
Title

Treatment of advanced non-small cell lung cancer in the elderly

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 1 (2011)

Article type

Review paper

Pages

1-8

Published online

2011-04-28

Bibliographic record

Onkol. Prak. Klin 2011;7(1):1-8.

Keywords

non-small-cell lung cancer
chemotherapy
elderly
geriatric oncology

Authors

Magdalena Knetki-Wróblewska
Adam Płużański
Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl